Dual Nucleoside Analogue Therapy for Feline Infectious Peritonitis: Rationale, Evidence, and Clinical Considerations

A review of the pharmacological rationale and emerging clinical evidence supporting combined GS-441524 and EIDD-1931 therapy in the management of Feline Infectious Peritonitis (FIP).

Introduction

Feline Infectious Peritonitis (FIP), caused by virulent biotypes of feline coronavirus (FCoV), has transitioned from a uniformly fatal disease to a treatable condition since the introduction of the nucleoside analogue GS-441524 in 2019. Standard-of-care protocols using GS-441524 monotherapy at 4-10 mg/kg for 84 days have demonstrated consistently high remission rates across effusive, non-effusive, ocular, and neurological presentations.

However, as with all single-agent antiviral regimens, monotherapy carries inherent limitations: the potential for viral resistance under prolonged selective pressure, suboptimal CNS penetration in neurological cases, and incomplete viral clearance in a subset of treated cats. These challenges mirror those long observed in human antiviral medicine, where combination therapy has become the standard approach for HIV (HAART), hepatitis C (DAA combinations), and increasingly for SARS-CoV-2.

CURE FIP™ Dual Antiviral Oral Capsules address these limitations by combining GS-441524 and EIDD-1931 (β-D-N4-hydroxycytidine) in a single oral formulation, applying the dual-mechanism principle to feline coronavirus treatment.

Pharmacological Rationale: Complementary Mechanisms of Action

GS-441524: Chain Termination

GS-441524 is an adenosine nucleoside analogue that, following intracellular phosphorylation to its active triphosphate form (GS-443902), acts as a substrate for the viral RNA-dependent RNA polymerase (RdRp). Upon incorporation into the nascent RNA strand, the 1'-cyano substitution causes steric clash with the RdRp active site, resulting in delayed chain termination and cessation of viral RNA synthesis (Murphy et al., Veterinary Microbiology, 2018).

Dual Nucleoside Analogue Therapy for Feline Infectious Peritonitis: Rationale, Evidence, and Clinical Considerations

In vitro studies in Crandell-Rees feline kidney (CRFK) cells demonstrated that GS-441524 is non-cytotoxic at concentrations 100-fold higher than the dose effective at inhibiting FIPV replication, indicating a wide therapeutic index. The half-life of approximately 24 hours in plasma supports once-daily dosing in most clinical scenarios.

EIDD-1931: Lethal Mutagenesis

EIDD-1931 (β-D-N4-hydroxycytidine, NHC) is the active metabolite of molnupiravir (EIDD-2801). Unlike chain-terminating nucleoside analogues, EIDD-1931 functions as a mutagenic ribonucleoside that is incorporated into viral RNA without causing immediate chain termination. Instead, it serves as a template for misincorporation during subsequent rounds of replication, alternating between cytidine and uridine base-pairing. This introduces transition mutations (C-to-U and G-to-A) at increasing frequency across the viral genome until the cumulative mutation burden exceeds the error threshold, resulting in viral population collapse through lethal mutagenesis (error catastrophe).

This mechanism is fundamentally distinct from chain termination and targets a different vulnerability in the viral replication cycle. Pharmacokinetic studies in cats with naturally occurring Feline Infectious Peritonitis (FIP) have confirmed that oral EIDD-1931 achieves mean peak serum concentrations (Cmax) of approximately 1,551 ng/mL (approximately 6 μM), with detectable levels sustained for at least 12 hours post-administration, supporting twice-daily dosing (Pharmacokinetics of Molnupiravir in Cats with Feline Infectious Peritonitis (FIP), Pathogens, 2025).

Synergistic Potential

The combination of a chain terminator (GS-441524) with a lethal mutagen (EIDD-1931) creates two simultaneous barriers to viral replication:

1. GS-441524 directly reduces the output of new viral RNA copies by terminating elongation.

2. EIDD-1931 degrades the fidelity of whatever RNA copies are produced, rendering them progressively nonfunctional.

This dual pressure reduces the effective viral population more rapidly than either agent alone and, critically, raises the genetic barrier to resistance by requiring the virus to simultaneously evolve escape mutations against two orthogonal mechanisms.

Clinical Evidence

GS-441524 Monotherapy

The evidence base for GS-441524 monotherapy is now substantial:

Pedersen et al. (2019) conducted the landmark field trial at UC Davis, treating 31 cats with naturally occurring Feline Infectious Peritonitis (FIP) (26 effusive, 5 non-effusive) using GS-441524 at 2.0-4.0 mg/kg SC q24h for a minimum of 12 weeks. Of the 26 cats that completed treatment, 18 remained in sustained remission at the time of publication, with 8 experiencing relapses that were managed with dose escalation. Fever resolution occurred within 12-36 hours and abdominal effusions resolved within 10-14 days in responding patients. J Feline Med Surg, 21(4):271-281

Coggins et al. (2023) reported outcomes from 307 cats treated with legally sourced veterinary-compounded remdesivir and/or GS-441524 in Australia and the UK. Three treatment protocols were used: remdesivir alone (33.9%), remdesivir followed by GS-441524 (55.7%), and GS-441524 alone (10.4%). At the longest follow-up (median 248 days), 84.4% of cats were alive. The relapse rate was 10.8% (33/307), with cats achieving a complete response within 30 days being significantly more likely to survive the initial treatment period. J Vet Intern Med

Krentz et al. (2024) conducted a prospective randomized controlled study at LMU Munich comparing 42-day versus 84-day oral GS-441524 treatment (15 mg/kg PO q24h) in 40 cats with effusive Feline Infectious Peritonitis (FIP). With the exception of two cats that died during treatment, all 38 remaining cats (19 per group) recovered with rapid improvement in clinical and laboratory parameters, along with significant reductions in viral RNA loads in blood and effusion. No significant difference in efficacy was observed between treatment durations. Pathogens, PMC11281457

Delaplace et al. (2025) published a systematic review following PRISMA guidelines, analyzing 11 studies encompassing 650 Feline Infectious Peritonitis (FIP) cases treated with GS-441524 alone or in combination. The overall treatment success rate was 84.6% (550/650). Success rates were higher with combination therapy and lower in effusive Feline Infectious Peritonitis (FIP) and cases with neurological complications. Effusive Feline Infectious Peritonitis (FIP) had an OR of approximately 0.49 for treatment success compared to non-effusive Feline Infectious Peritonitis (FIP). Notably, in neurological cases treated with GS-441524 combined with other antivirals, outcomes were markedly improved: 10/10 neurological cases treated with GS-441524 + remdesivir survived, and 7/8 treated with GS-441524 + GC376 survived. Pathogens, PMC12298711

Molnupiravir/EIDD-1931

Kanai et al. (2023) reported the first published case series of molnupiravir for Feline Infectious Peritonitis (FIP) treatment. Eighteen cats (13 effusive, 5 non-effusive, including 3 with neurological/ocular signs) were treated with compounded molnupiravir at 10-20 mg/kg PO q12h for 84 days. Four cats with effusive Feline Infectious Peritonitis (FIP) died or were euthanized within 7 days of treatment initiation. The remaining 14 cats completed treatment and remained in remission at 139-206 days follow-up. Transient ALT elevations were observed in 3 cats (days 7-9), all resolving without intervention. J Vet Intern Med

Kanai et al. (2024) expanded this work in a comparative study of 118 cats (76 effusive), with 59 receiving GS-441524 and 59 receiving molnupiravir. Mortality was comparable: 12/59 (20.3%) in the GS-441524 group and 8/59 (13.6%) in the molnupiravir group (p = 0.326), with most deaths occurring within the first 10 days. Among cats completing treatment, remission was achieved in 48/48 GS-441524-treated cats and 51/52 molnupiravir-treated cats. Neurological and ocular signs resolved in all but one cat. Adverse events, primarily transient hepatic enzyme elevations, were comparable between groups. Front Vet Sci

Roy et al. (2022) documented molnupiravir as a rescue therapy at Ohio State University. Twenty-six cats with suspected Feline Infectious Peritonitis (FIP) who had failed or relapsed on unlicensed GS-441524-based therapy were treated with molnupiravir at a mean starting dose of 12.8 mg/kg and ending dose of 14.7 mg/kg q12h for a median of 12 weeks. At the time of writing, 24/26 cats were living disease-free. Notable adverse effects (folded ears, broken whiskers, severe leukopenia) were observed only at dosages exceeding 23 mg/kg q12h. Pathogens, PMC9612227

Combination Antiviral Therapy in Feline Infectious Peritonitis (FIP)

Li et al. (2022) investigated the combination of GS-441524 with the 3C-like protease inhibitor GC376 in 46 cats with naturally occurring Feline Infectious Peritonitis (FIP) (36 wet, 10 dry). Cats received varying dose combinations of GS-441524 (2.5-5.0 mg/kg SC q24h) and GC376 (10-20 mg/kg SC q12h) for four weeks. After the combination treatment period, 45/46 (97.8%) cats survived, with 43 becoming clinically normal by end of treatment and 2 requiring extended GS-441524 monotherapy (7-12 additional weeks). All 45 surviving cats remained alive and relapse-free at 10 months post-treatment. Front Vet Sci, 10.3389/fvets.2022.1002488

Broader Virology: Combination Therapy and Resistance Prevention

Wagoner et al. (2023) demonstrated in Calu-3 lung epithelial cell models that combining molnupiravir with host-targeting antivirals (TMPRSS2 inhibitors) synergistically suppressed SARS-CoV-2, with potency comparable to the all-DAA combination of molnupiravir plus nirmatrelvir. Triple combinations further increased antiviral potency. The authors concluded that combination regimens can enhance antiviral potency, reduce the emergence of drug-resistant variants, and lower the dose of each component. Microbiology Spectrum

A comprehensive 2025 review in npj Antimicrobials and Resistance confirmed that combining antiviral agents with different resistance profiles and mechanisms of action creates a higher genetic barrier to resistance development. The review highlighted that combination therapy with molnupiravir and other antivirals targeting different stages of the viral life cycle produced synergistic effects across multiple coronavirus models. npj Antimicrobials and Resistance

Clinical Considerations for Dual Therapy

Neurological Feline Infectious Peritonitis (FIP)

Neurological Feline Infectious Peritonitis (FIP) remains the most challenging presentation, with lower treatment success rates even at escalated GS-441524 dosages (10-15 mg/kg). CSF penetration of GS-441524 is approximately 7-21% of blood levels, varying between individual cats. The 2025 systematic review demonstrated that combination therapy significantly improved neurological Feline Infectious Peritonitis (FIP) outcomes compared to GS-441524 monotherapy. The addition of EIDD-1931, which operates through a complementary mutagenic mechanism, provides supplementary antiviral pressure that may compensate for suboptimal CNS drug levels of either agent alone.

Resistance Mitigation

Drug resistance to GS-441524 during prolonged monotherapy has been documented in the veterinary literature, typically manifesting as poor initial response or regression during treatment. The 84-day treatment duration creates sustained selective pressure favoring resistant viral variants. Dual-mechanism therapy raises the genetic barrier to resistance by requiring the virus to simultaneously acquire escape mutations against both chain termination and lethal mutagenesis, a substantially less probable evolutionary event.

Incomplete Remission and Relapse

Approximately 10-11% of GS-441524-treated cats experience relapse. In the Coggins et al. (2023) retrospective, 33/307 (10.8%) cats relapsed, with roughly equal distribution during and after the initial treatment period. Dual antiviral therapy may reduce residual viral reservoirs more effectively than monotherapy, thereby lowering relapse risk. EIDD-1931 has also been used successfully as a rescue agent for GS-441524-refractory cases, suggesting complementary antiviral coverage.

Dosing and Administration

CURE FIP™ Dual Antiviral Oral Capsules combine precisely calibrated amounts of GS-441524 and EIDD-1931 in a single capsule, simplifying the treatment protocol. The single-capsule format eliminates the complexity of managing two separate medications with different dosing schedules, supporting treatment adherence over the 84-day course. Dosage should be determined by body weight and Feline Infectious Peritonitis (FIP) presentation using the CureFIP Dosage Calculator.

Calicivirus Co-infection

EIDD-1931 has demonstrated in vitro activity against feline calicivirus (FCV), providing additional clinical utility in cats presenting with concurrent Feline Infectious Peritonitis (FIP) and FCV infection.

Monitoring Recommendations

Standard monitoring protocols for GS-441524 monotherapy remain applicable during dual antiviral therapy. Clinicians should monitor:

• Complete blood count (CBC) with attention to neutrophil counts, given the potential for transient neutropenia with EIDD-1931 at higher dosages

• Serum biochemistry with particular attention to ALT activity, as transient hepatic enzyme elevations have been reported with both agents

• Body weight and clinical signs at regular intervals throughout the 84-day course

• Post-treatment observation for a minimum of 12 weeks to monitor for relapse

Summary

The combination of GS-441524 and EIDD-1931 represents a pharmacologically rational evolution in Feline Infectious Peritonitis (FIP) treatment, applying established principles of combination antiviral therapy to feline coronavirus. By targeting viral replication through two orthogonal mechanisms (chain termination and lethal mutagenesis), dual therapy offers enhanced viral suppression, a higher genetic barrier to resistance, and potentially improved outcomes in challenging presentations such as neurological Feline Infectious Peritonitis (FIP).

While dedicated clinical trials evaluating the specific GS-441524 + EIDD-1931 combination are ongoing, the existing evidence base for each agent individually, combined with the strong evidence supporting combination antiviral strategies across virology, provides a compelling rationale for dual nucleoside analogue therapy in Feline Infectious Peritonitis (FIP) management.

References

1. Pedersen NC, Perron M, Bannasch M, et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. 2019;21(4):271-281. PubMed

2. Murphy BG, Perron M, Murakami E, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (Feline Infectious Peritonitis (FIP)) virus in tissue culture and experimental cat infection studies. Vet Microbiol. 2018;219:226-233.

3. Coggins SJ, Norris JM, Malik R, et al. Outcomes of treatment of cats with feline infectious peritonitis using parenteral remdesivir, with or without transition to oral GS-441524. J Vet Intern Med. 2023. PubMed

4. Krentz D, Zenger K, Alberer M, et al. Short treatment of 42 days with oral GS-441524 results in equal efficacy as the recommended 84-day treatment in cats suffering from feline infectious peritonitis with effusion. Pathogens. 2024. PMC

5. Delaplace M, Huet H, Gambino A, Le Poder S. Efficacy of GS-441524 for feline infectious peritonitis: a systematic review (2018-2024). Pathogens. 2025. PMC

6. Kanai Y, Ishijima Y, Ishikawa S, et al. Molnupiravir treatment of 18 cats with feline infectious peritonitis: a case series. J Vet Intern Med. 2023. PubMed

7. Kanai Y, Ishijima Y, Ishikawa S, et al. GS-441524 and molnupiravir are similarly effective for the treatment of cats with feline infectious peritonitis. Front Vet Sci. 2024. Frontiers

8. Roy M, Jacque N, Engwall-Gill AJ, et al. Unlicensed molnupiravir is an effective rescue treatment following failure of unlicensed GS-441524-like therapy for cats with suspected feline infectious peritonitis. Pathogens. 2022. PMC

9. Li Y, Wang H, Jin J, et al. Effect of GS-441524 in combination with the 3C-like protease inhibitor GC376 on the treatment of naturally transmitted feline infectious peritonitis. Front Vet Sci. 2022;9:1002488. Frontiers

10. Wagoner J, Herring S, Hsiang TY, et al. Combinations of host- and virus-targeting antiviral drugs confer synergistic suppression of SARS-CoV-2. Microbiol Spectr. 2023. ASM

11. Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals. npj Antimicrob Resist. 2025. Nature

12. Pharmacokinetics of molnupiravir in cats with naturally occurring feline infectious peritonitis. Pathogens. 2025. MDPI

For treatment protocols, dosage calculations, and clinical consultation, visit curefip.com or contact the CureFIP veterinary support team at europe@curefip.com.